Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous vs Intravenous Piperacillin/Tazobactam in Adults With Infection
NCT07481539Phase 2Recruiting
- Sponsor
- Azienda sanitaria universitaria Friuli Centrale
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of piperacillin, tazobactam in bacterial infection, pneumonia, neutropenic fever, sponsored by Azienda sanitaria universitaria Friuli Centrale. Started Mar 2026; status: recruiting.
02
Drugs
piperacillintazobactam
03
Conditions
bacterial infectionpneumonianeutropenic fever
Beyond the preview
Go deeper on NCT07481539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07481539.